This company listing is no longer active
DSM2 Stock Overview
DSM-Firmenich AG provides solutions for nutrition, health, and beauty businesses in the Switzerland, Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia.
Snowflake Score | |
---|---|
Valuation | 6/6 |
Future Growth | 4/6 |
Past Performance | 1/6 |
Financial Health | 6/6 |
Dividends | 4/6 |
Rewards
Risk Analysis
DSM-Firmenich AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$113.95 |
52 Week High | US$157.30 |
52 Week Low | US$106.00 |
Beta | 0.72 |
1 Month Change | -3.14% |
3 Month Change | -3.06% |
1 Year Change | -28.11% |
3 Year Change | -3.76% |
5 Year Change | 28.73% |
Change since IPO | 105.32% |
Recent News & Updates
Recent updates
Shareholder Returns
DSM2 | Chemicals | Market | |
---|---|---|---|
7D | 0.3% | 0% | 0% |
1Y | -28.1% | 0% | 0% |
Return vs Industry: DSM2 underperformed the German Chemicals industry which returned -12.6% over the past year.
Return vs Market: DSM2 underperformed the German Market which returned -8.2% over the past year.
Price Volatility
DSM2 volatility | |
---|---|
DSM2 Average Weekly Movement | 3.4% |
Chemicals Industry Average Movement | 0% |
Market Average Movement | 0% |
10% most volatile stocks in DE Market | 0% |
10% least volatile stocks in DE Market | 0% |
Stable Share Price: DSM2 has not had significant price volatility in the past 3 months.
Volatility Over Time: DSM2's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1902 | 19,973 | Dimitri de Vreeze | https://www.dsm-firmenich.com |
DSM-Firmenich AG Fundamentals Summary
DSM2 fundamental statistics | |
---|---|
Market cap | n/a |
Earnings (TTM) | 0 |
Revenue (TTM) | n/a |
1.7x
P/E Ration/a
P/S RatioIs DSM2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
DSM2 income statement (TTM) | |
---|---|
Revenue | US$8.39b |
Cost of Revenue | US$5.70b |
Gross Profit | US$2.69b |
Other Expenses | US$2.24b |
Earnings | US$454.00m |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 67.80 |
Gross Margin | 32.06% |
Net Profit Margin | 5.41% |
Debt/Equity Ratio | 26.6% |
How did DSM2 perform over the long term?
See historical performance and comparison